பாலம் தடுப்பூசி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பாலம் தடுப்பூசி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பாலம் தடுப்பூசி Today - Breaking & Trending Today

ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. .
ADMA Biologics, Inc.February 26, 2021 GMT
Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae
to Bridge Vaccination and Seroconversion Across Multiple Serotypes
By Using as an Add-On with a Vaccine or Antibiotics, This Therapeutic Strategy has the Potential to Improve S. Pneumoniae
-Related Hospital Clinical Outcomes
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 26, 2021 (GLOBE NEWSWIRE) ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the presentation of a late-breaking poster at the 2021 American Academy of Allergy, Asthma & Immunology Confer ....

United States , Boca Raton , Sam Martin , Adam Grossman , Biologics Inc , Securities Exchange , Drug Administration , American Academy Of Allergy , Poster Presentation Highlights , Polyclonal Hyperimmune Globulin Targeting , Bridge Vaccination , Seroconversion Across Multiple , Therapeutic Strategy , Related Hospital Clinical , Immunology Conference , Virtual Annual Meeting , Chief Executive Officer , Cross Stakeholder Qualitative Study , Potential Utility , Hyperimmune Globulin , Vulnerable Populations , Poster Abstract Sessions , Virtual Poster Hall , United States Food , Securities Act , Securities Exchange Act ,

ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting


Session Dates: Friday, February 26 – Monday, March 1, 2021
Session Location: Virtual Poster Hall
Poster No: L30
About ADMA Biologics, Inc.
ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures i ....

United States , Boca Raton , Adam Grossman , Biologics Inc , Securities Exchange , Drug Administration , American Academy Of Allergy , Presentation Highlights , Polyclonal Hyperimmune Globulin Targeting , Bridge Vaccination , Seroconversion Across Multiple , Therapeutic Strategy , Related Hospital Clinical , Immunology Conference , Virtual Annual Meeting , Chief Executive Officer , Cross Stakeholder Qualitative Study , Potential Utility , Hyperimmune Globulin , Vulnerable Populations , Poster Abstract , Virtual Poster , United States Food , Securities Act , Securities Exchange Act , Investor Relations ,